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Cytokine-induced beta-cell apoptosis is important
to the etiology of type-1 diabetes. Although previous
reports have shown that general inhibitors of histone
deacetylase (HDAC) activity, such as suberoylanilide
hydroxamic acid and trichostatin A, can partially
prevent beta-cell death, they do not fully restore
beta-cell function. To understand HDAC isoform
selectivity in beta cells, we measured the cellular
effects of 11 structurally diverse HDAC inhibitors on
cytokine-induced apoptosis in the rat INS-1E
cell line. All 11 compounds restored ATP levels
and reduced nitrite secretion. However, caspase-3
activity was reduced only by MS-275 and CI-994,
both of which target HDAC1, 2, and 3. Importantly,
bothMS-275 and genetic knockdown ofHdac3 alone
were sufficient to restore glucose-stimulated insulin
secretion in the presence of cytokines. These results
suggest that HDAC3-selective inhibitors may be
effective in preventing cytokine-induced beta-cell
apoptosis.INTRODUCTION
Type-1 diabetes involves autoimmune attack of insulin-
producing beta cells in the pancreas. The inflammatory cyto-
kines interleukin-1b (IL-1b), interferon-g (IFN-g), and tumor
necrosis factor-a (TNF-a) are important mediators in the
impaired function and destruction of pancreatic beta cells
(Cnop et al., 2005; Fornoni et al., 2008; Soldevila et al., 1991)
and are commonly used in vitro to mimic the events leading to
beta-cell apoptosis. IL-1b and TNF-a induce NFkB expression,
and downstream gene expression is thought to be regulated
by nitric oxide (NO) signaling, which increases endoplasmic
reticulum stress-response pathways and decreases beta-cell-
specific functions (Darville and Eizirik, 1998). NO is a highly
reactive molecule that inhibits the electron-transport chain,
decreasing glucose oxidation rates, ATP generation, and insulin
production; cellular nitrite is more stable and serves as a surro-
gate marker for NO. NFkB activation and IFN-g-inducedChemistry & Biology 19,STAT-1 signaling work together to induce beta-cell death
by the intrinsic apoptotic pathway (Grunnet et al., 2009), in-
cluding the loss of glucose-stimulated insulin secretion (GSIS),
one of the most important physiological functions of beta cells.
Small molecules capable of preventing cytokine-induced beta-
cell apoptosis could lead to new avenues for therapeutic
intervention.
Recently, an important role for histone deacetylases (HDACs)
in suppressing beta-cell apoptosis was suggested, perhaps by
decreasing NFkB transactivation (reviewed in Christensen
et al., 2011). Larsen et al. (2007) demonstrated that the HDAC
inhibitors SAHA and trichostatin A (TsA) partially prevented cyto-
kine-induced beta-cell toxicity. However, neither SAHA nor TsA
could restore GSIS. ITF2357, another broad-spectrum HDAC
inhibitor, had in vivo activity, protecting mouse islets from
cytokines and preventing hyperglycemia in streptozocin-treated
mice (Lewis et al., 2011).
Histone deacetylases (HDACs) regulate gene transcription
by modulating the lysine acetylation of histones. A number of
HDAC inhibitors have been developed to study chromatin
biology and are clinical candidates for cancer therapy (Minucci
and Pelicci, 2006). Recently, a study demonstrated that osten-
sibly broad-spectrum HDAC inhibitors actually display different
biochemical isoform selectivities (Bradner et al., 2010). For
example, suberoylanilide hydroxamic acid (SAHA) inhibits the
activities of HDAC1, 2, 3, 6, and 8, while MS-275 only inhibits
the activities of HDAC1, 2, and 3. Based on these results, we
reasoned that a more selective HDAC inhibitor could be more
beneficial to beta-cell survival. To that end, we examined a struc-
turally diverse panel of HDAC inhibitors, and genetically knocked
down individual isoforms in the rat cell line INS-1E. Our results
demonstrate that inhibition of HDAC3 appears to be sufficient
to suppress beta-cell apoptosis in this system, and point to
this enzyme as a potential target for preventing beta-cell
apoptosis.
RESULTS AND DISCUSSION
Using cellular ATP levels as a surrogate for cell viability (Chou
et al., 2010), we tested the effects of 11 structurally diverse
HDAC inhibitors (Figure S1 available online) in protecting the
rat INS-1E insulinoma cell line (Merglen et al., 2004) from cyto-
kine-induced apoptosis. Most of the compounds tested sup-
pressed the inhibitory effects of cytokines on ATP levels to669–673, June 22, 2012 ª2012 Elsevier Ltd All rights reserved 669
Figure 1. Phenotypic Profiling of 11 HDAC Inhibitors in Beta Cells
(A–C) INS-1E cells were treated for 48 hr with a cocktail of proinflammatory cytokines (see Experimental Procedures) in the absence or presence of 11 HDAC
inhibitors, and were assessed for cellular ATP levels (A), caspase-3 activity (B), and nitrite production (C). Concentrations used were: PXD101, 0.2 mM; SAHA,
1 mM; pyroxamide, 5 mM; LAQ824, 1 mM; apicidin, 0.05 mM; trichostatin A, 0.05 mM; scriptaid, 1 mM; 3, 5 mM; APHA, 5 mM; CI-994, 10 mM; andMS-275, 5 mM. Data
represent the mean ± standard deviation of 24 independent wells.
(D) Data in (A), (B), and (C) are represented as a heat map. Activity for each compound treatment was scaled to a range of 1 (green), indicating a decrease in
signal relative to the cytokine-treated state (NT), to 1 (red), indicating an increase in signal relative to the cytokine-treated state. The profile for each compound
indicates the extent to which each assay was restored to the untreated (no cytokine) state.
(E) The chemical structures of HDAC inhibitors studied in more detail: 1 (MS-275), 2 (SAHA), 3 (Methot et al., 2008), and 4 (CI-994).
See also Figures S1 and S2.
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different effects on caspase-3 activity after compound treat-
ment. MS-275 and CI-994 were the only two compounds that
reduced caspase-3 activity significantly, while other HDAC
inhibitors either were inactive or, like PXD101 and SAHA, even
increased caspase-3 activity (Figure 1B). Most compounds
only slightly decreased nitrite secretion, a surrogate for nitric
oxide production, which was induced by cytokine treatment
(Figure 1C). When we performed hierarchical clustering on the
data, the compounds with the most beneficial effects on cyto-
kine-treated beta cells clustered together, and in particular
were those that selectively inhibited the activities of HDAC1,
2, and 3 (MS-275 and CI-994) (Figures 1D and 1E). These results
suggest that only certain HDAC isoforms are important to cyto-
kine-induced beta-cell apoptosis, and that the selectivity of
HDAC inhibitors is an important consideration in assessing this
activity.
These measurements were made at a single compound
concentration, the highest at which the cells remained viable
(Figure S2). In order to determine concentration dependence,
we tested MS-275 and SAHA as exemplars of class I (HDAC1,
2, 3) and broad-spectrum inhibition, respectively, over a 4- to
5-fold range of concentrations. BothMS-275 and SAHA restored
ATP levels in INS-1E cells treated with cytokines, with SAHA
resulting in a greater suppression (Figure 2A). However, SAHA
slightly increased caspase-3 activity, while MS-275 reduced
caspase-3 activity in the presence of cytokines by approxi-670 Chemistry & Biology 19, 669–673, June 22, 2012 ª2012 Elseviermately 50% (Figure 2B). MS-275 was also more effective in
restoring mitochondrial membrane potential, another readout
of apoptosis, than SAHA (Figure S3). MS-275 and SAHA resulted
in comparable reduction of nitrite production in the presence of
cytokines (Figure 2C). Consistent with previous reports that
SAHA could not restore the impairment in GSIS caused by treat-
ment with cytokines (Larsen et al., 2007), we confirmed that 1 mM
SAHA had no effect on GSIS, while 5 mMMS-275 restored GSIS
in the presence of cytokines (Figure 2D). These results suggest
that MS-275 may be a superior suppressor of cytokine-induced
beta-cell apoptosis than less selective HDAC inhibitors.
We then sought to determine the HDAC isoform(s) responsible
for suppression of cytokine-induced beta-cell apoptosis.
MS-275 is a selective inhibitor of HDAC1, 2, and 3, while SAHA
additionally inhibits HDAC6 and 8 (Bradner et al., 2010). We
reasoned that inhibition of HDAC1, 2, or 3 led to the protective
effects of MS-275. To test this hypothesis, we performed
gene-silencing experiments targeting these HDACs using
small-interfering RNA (siRNA). siRNA duplexes specific for
Hdac1, Hdac2, or Hdac3 were transfected into INS-1E cells,
leading to a selective decrease in protein expression of the
appropriate HDAC (Figure S4). Each knockdown alone had no
effect on viability (Figure S5). Knockdown of Hdac2 or Hdac3
in the presence of cytokines resulted in a 35% restoration of
ATP levels, while knockdown of Hdac1 had no effect (Figures
3A and S6). We thus proceeded to examine the effects of
knocking down Hdac2 or Hdac3. Only knockdown of Hdac3Ltd All rights reserved
Figure 2. Cytokine-Induced Apoptosis is
Suppressed by MS-275 but Not SAHA
(A) Effects of MS-275 and SAHA on cellular ATP
levels in INS-1E cells after 48 hr in the presence of
the cytokine cocktail.
(B) Effects of MS-275 and SAHA on caspase-3
activity after 48 hr treatment.
(C) Effects of MS-275 and SAHA on the cellular
production of nitrite after 48 hr treatment.
(D) Effects of MS-275 and SAHA on glucose-
stimulated insulin secretion after 48 hr treatment.
Data represent the mean ± SD of 8 independent
wells for insulin secretion and 24 independent
wells for others. * indicates p < 0.01 as compared
to the cytokine treatment alone.
See also Figure S3.
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HDAC3 Inhibition in Beta-Cell Apoptosiswas sufficient to reduce caspase-3 activity (Figure 3B). Knock-
down of either Hdac2 or Hdac3 resulted in slight but statistically
significant reduction in nitrite production (Figure 3C) and
increase in mitochondrial membrane potential (Figure S4), while
again knockdown of Hdac1 had no effect. We observed similar
effects using a cell-death ELISA to measure DNA-histone
complexes released into the cytoplasm (Figure S7). Importantly,
knockdown ofHdac3 alone led to restoration ofGSIS (Figure 3D),
showing that the beta cells are fully functional. Knockdown of
Hdac1 resulted in a moderate but statistically insignificant resto-
ration of GSIS in INS-1E cells (Figure S8), and the restoration was
to a lesser extent than with Hdac3 knockdown. These results
indicate that inhibition of HDAC3 is primarily responsible for
the protective effects of MS-275 on beta cells in the presence
of inflammatory cytokines. Further, insulin secretion does not
appear to be correlated with ATP levels alone but rather is
more related to caspase activity.
To further demonstrate the importance of HDAC3 in protecting
insulin-secreting cells from cytokine-induced apoptosis, we
used small-molecule inhibitors to chemically isolate HDAC3
activity. CI-994, an inhibitor selective for HDAC1, 2, and 3,
restored ATP levels and reduced caspase-3 activity in INS-1E
cells (Figures 4A and 4B). A 2-thiophenyl analog of CI-994, 3 (Fig-
ure 1B), exhibits inhibitory activity toward HDAC1 and 2 only
(IC50 7 and 49 nM, respectively, versus 10 mM for HDAC3)
(Methot et al., 2008). Thus, we could indirectly assess the effects
of HDAC3 inhibition by comparing the activities of 3 and CI-994.
Although 3 restored ATP levels (Figure 4A), it did not reduce
caspase-3 activity (Figure 4B). Mitochondrial membrane poten-
tial was completely restored by CI-994, but not by 3 (Figure S9).
These results further demonstrate the crucial role of HDAC3 in
cytokine-induced beta-cell apoptosis. Importantly, these dataChemistry & Biology 19, 669–673, June 22, 2012are limited to beta-cell lines; study in
primary islets will enable target validation
for future therapeutic development.
In conclusion, we evaluated a panel of
11 clinically advanced HDAC inhibitors
and found that MS-275 and CI-994
suppress cytokine-induced beta-cell
apoptosis, while the less selective inhibi-
tors SAHA and TsA do not. By comparing
these results to biochemical activities, wenarrowed down the possible HDAC targets to a combination of
HDAC1, 2, or 3. Using siRNA reagents and isoform-selective
inhibitors, we observed that inhibition of HDAC3 appears to be
critical for the protective effects of HDAC inhibitors, while the
inhibition of additional isoforms may be deleterious to beta-cell
function. It is possible that theremay be further protective effects
on beta-cell physiology after HDAC1 inhibition as well. The lack
of correlation between ATP levels and caspase activity after
treatment with some of these compounds suggests that these
assays are reading out different aspects of cell toxicity. This
notion is consistent with a previous analysis of the lack of overlap
between viability assay readouts in hepatoma cells (Miret et al.,
2006). This study suggests the importance of developing more
selective HDAC3 inhibitors and exploring their potential uses in
protecting pancreatic beta cells from inflammatory attack during
the development of type-1 diabetes.
SIGNIFICANCE
Illuminating the mechanism of inflammatory cytokine-
induced beta-cell apoptosis will be important for under-
standing the etiology of type-1 diabetes. Small molecules
capable of suppressing this apoptotic process may be suit-
able candidates for developing therapies to protect beta
cells from autoimmune attack. Initial reports demonstrated
that inhibition of histone deacetylase (HDAC) activity may
be protective to beta cells (Larsen et al., 2007). However,
broad-spectrum HDAC inhibitors cannot restore critical
beta-cell functions such as glucose-stimulated insulin
secretion, and may be toxic on their own. Thus, we sought
to determine the isoform(s) responsible for beta-cell survival
in this process. Here, we have demonstrated that bothª2012 Elsevier Ltd All rights reserved 671
Figure 3. Genetic Knockdown of Hdac3
Suppresses Beta-Cell Apoptosis
The effects of knocking down Hdac1, 2, or 3 on (A)
cellular ATP levels, (B) caspase-3 activity, (C)
nitrite production, or (D) glucose-stimulated insulin
secretion. Data represent the mean ± SD of 8
independent wells for insulin secretion and 24
independent wells for others. * indicates p < 0.01
as compared to the cytokine treatment alone.
See also Figures S4, S5, S6, S7, and S8.
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suppress apoptosis in a rat beta-cell line. Small molecules
selective for HDAC1, 2, or 3 were more restorative to beta-
cell function than broad-spectrum inhibitors like SAHA,
suggesting that inhibition of additional HDAC isoforms
causes additional toxicity to these cells. Most importantly,
glucose-stimulated insulin secretion was restored by selec-
tive compounds such asMS-275, and by genetic knockdown
of Hdac3. Future efforts to determine the cellular events
regulated by HDAC3 in response to cytokine treatment,
why inhibition of other isoforms may be toxic, and assess-
ment of this effect in primary beta cells, will help clarify the
pathways involved in the development of type-1 diabetes.
EXPERIMENTAL PROCEDURES
Cell Culture and Reagents
INS-1E cells (generously provided by Claes Wollheim and Pierre Maechler,
University of Geneva, Switzerland) were maintained in culture medium (RPMI
1640, containing 11 mM glucose, 10% fetal bovine serum, 10 mM HEPES,
50 mM 2-mercaptoethanol, and 1 mM sodium pyruvate) and cultivated at
37C with 5% CO2 in a humidified atmosphere. In all compound-treatment
experiments, final DMSO concentrations were kept to less than 0.5%.
Recombinant rat IL-1b and recombinant mouse TNF-a were purchased from
R&D Systems. Recombinant mouse IFN-g and Griess reagent were purchased
from Sigma. CellTiter-Glo and Caspase-Glo 3/7 reagents were purchased
from Promega. Rabbit antibodies for HDAC1, 2 and 3 were from CellSignaling.
Mouse monoclonal antibody to tubulin was from Sigma. Secondary horse-
radish-peroxidase-conjugated goat anti-mouse and anti-rabbit antibodies
were from Thermo Fisher Scientific. HDAC inhibitors were purchased from
Sigma or synthesized in-house.
Measurement of Cellular ATP Levels
INS-1E cells were seeded at 10,000 cells/well using a Multidrop Combi
(Thermo Labsystems) in white optical 384-well plates (Corning Life Sciences).
After overnight incubation, medium was removed and 50 ml RPMI containing672 Chemistry & Biology 19, 669–673, June 22, 2012 ª2012 Elsevier Ltd All rights reservedthe treated compound, 1% FBS, and a combina-
tion of cytokines (10 ng/ml IL-1b, 50 ng/ml IFN-g,
and 25 ng/ml TNF-a) was added to every well.
After incubation for 48 hr, medium was removed
and 20 ml CellTiter-Glo reagent was added. Lumi-
nescence was measured after 10 min incubation
using an EnVision plate reader (PerkinElmer).
Measurement of Cellular Nitrite Production
INS-1E cells were seeded at 10,000 cells/well
using a Multidrop Combi (Thermo Labsystems) in
white optical 384-well plates (Corning Life
Sciences). After overnight incubation, medium
was removed and 50 ml RPMI containing the
treated compound, 1% FBS, and a combination
of cytokines (10 ng/ml IL-1b, 50 ng/ml IFN-g, and25 ng/ml TNF-a) was added to every well. After treatment with cytokine and
compounds for 48 hr, 10 ml modified Griess reagent (1:1 mixture of 1% sulfa-
nilamide in 30% acetic acid and 0.1% N-(1-naphthyl) ethylenediamine dihy-
drochloride in 60% acetic acid) was added to each well. After 5 min incubation
at room temperature, the absorbance at 540 nm was measured using an
Envision plate reader (PerkinElmer).
Measurement of Mitochondrial Membrane Potential
Upon depolarization, the JC-1 dye is converted from a diffuse green form to
red fluorescent J-aggregates. The ratio of red to green fluorescence serves
as a readout of the mitochondrial membrane potential (Reers et al., 1995).
INS-1E cells were seeded at 10,000 cells/well using a Multidrop Combi
(Thermo Labsystems) in white optical 384-well plates (Corning Life Sciences).
After overnight incubation, medium was removed and 50 ml RPMI containing
the treated compound, 1% FBS, and a combination of cytokines (10 ng/ml
IL-1b, 50 ng/ml IFN-g, and 25 ng/ml TNF-a) was added to every well. After
treatment with cytokine and compounds for 48 hr, 20 ml of 3.25 mM JC-1
was added to each well. After 3 hr incubation at 37C, the cells were gently
washed three times with 50 ml per well of 1X calcium- and magnesium-free
PBS. Fluorescence was measured with an EnVision plate reader (PerkinElmer)
at the rhodamine spectra (excitation/emission 530 nm/580 nm) followed by
fluorescein (excitation/emission 485 nm/530 nm). The ratio of rhodamine to
fluorescein intensity was determined and represents the degree of mitochon-
drial membrane potential.
Caspase-3 Activity Assay
INS-1E cells were seeded at 5,000 cells/well using aMultidrop Combi (Thermo
Labsystems) in white optical 384-well plates (Corning Life Sciences). After
overnight incubation, medium was removed and 50 ml RPMI containing the
treated compound, 1% FBS, and a combination of cytokines (10 ng/ml
IL-1b, 50 ng/ml IFN-g, and 25 ng/ml TNF-a) was added to every well. After
treatment with cytokines and compounds for 48 hr, medium was removed
and 20 ml Caspase-Glo 3/7 reagent was added. Luminescence was measured
after 2 hr incubation using an Envision plate reader (PerkinElmer).
RNA Interference and Western Blotting
Small-interfering RNAs against Hdac1, 2, and 3 were obtained from Dharma-
con. siRNAs (100 nM) were transfected into INS-1E cells (5,000 cells/well in
Figure 4. Analysis of Chemical HDAC3
Inhibition on Beta-Cell Apoptosis
(A and B) Effects of 3 and 4 (CI-994) on (A) cellular
ATP levels and (B) caspase-3 activity in the pres-
ence of cytokines. Data represent the mean ± SD
of 24 independent wells. * indicates p < 0.01 as
compared to the cytokine treatment alone.
See also Figure S9.
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HDAC3 Inhibition in Beta-Cell Apoptosisa 384-well plate) using DharmaFECT reagent. Transfected cells were cultured
for 72 hr, then collected for Western blot analysis and cell-based assays. For
Western blotting, cells were lysed in RIPA buffer (20 mM Tris-HCl [pH 7.5],
150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% NP-40, 1% sodium deoxy-
cholate, 2.5 mM sodium pyrophosphate, 1 mM beta-glycerophosphate,
1 mM Na3VO4, and 1 mg/ml leupeptin). Total protein was separated by
4%–12% SDS-PAGE and transferred to a PVDF membrane. Blots were devel-
oped using the chemiluminescence detection system SuperSignal (Thermo
Fisher Scientific) and light emission was captured using an Imaging Station
4000MM (Carestream).
Glucose-Stimulated Insulin Secretion
INS-1E cells were seeded in 96-well plates at 20,000 cells/well in 100 ml RPMI
and incubated for 48 hr in 100 ml fresh RPMI containing 1% FBS and the
cytokine cocktail in the presence or absence of 5 mM MS-275. Cells were
washed and incubated for 2 hr in KRBH buffer (135 mM NaCl, 3.6 mM KCl,
5 mM NaHCO3, 0.5 mM NaH2PO4, 0.5 mM MgCl2, 1.5 mM CaCl2, 10 mM
HEPES [pH 7.4], and 0.1% BSA) lacking glucose. Cells were subsequently
incubated with KRBH buffer containing 2 mM or 16 mM glucose for 1 hr.
The supernatant was collected for measurement of secreted insulin. Insulin
was measured with a rat insulin ELISA kit (Alpco).
SUPPLEMENTAL INFORMATION
Supplemental Information includes eight figures and can be found with this
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